Elkedonia is a pioneering start-up company committed to transforming the treatment of mental health disorders. Our mission is to develop a new generation of antidepressants that are fast-acting, highly effective, and safe.
Our breakthrough approach is based on first-in-class neuroplastogens, which promote neuroplasticity without the side effects of psychedelics and ketamine. By eliminating risks of dependence, sedation, or psychotic effects, our innovative treatments empower patients to rediscover the joys of life while significantly reducing the risk of relapse and suicide.
At Elkedonia, we believe in a future where mental health treatments enhance well-being without compromise. Join us in this therapeutic revolution.
đ§ Innovating for better mental health.
Company Details
- Employees
- 6
- Founded
- -
- Address
- Strasbourg, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://elkedonia.com/
- HQ
- Strasbourg
Elkedonia Questions
Elkedonia's website is https://elkedonia.com/
Elkedonia's LinkedIn profile is https://fr.linkedin.com/company/elkedonia
Elkedonia has
6 employees.
View email and phone details for 6
employees at Elkedonia.
Elkedonia's industry is
Biotechnology Research
Elkedonia's top competitors are
Astrivax Therapeutics,
Inverna Therapeutics,
Perseus Biomics,
Crucible Therapeutics,
Argobio Studio,
Railroad Therapeutics,
One2treat,
Spica Therapeutics,
Onco3r Therapeutics,
Atbtherapeutics.
Elkedonia's categories are Biotechnology Research
Elkedonia's founding year is 2025
